专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0200693A3 RESPIRATORY SYNCYTIAL VIRUS VACCINES EXPRESSING PROTECTIVE ANTIGENS FROM PROMOTOR-PROXIMAL GENES 审中-公开
标题翻译：呼吸道合胞病毒疫苗表达启动子 - 近邻基因的保护性抗原
公开(公告)号：WO0200693A3
公开(公告)日：2002-09-26
申请号：PCT/US0120107
申请日：2001-06-22
申请人： US GOV NAT INST HEALTH , KREMPL CHRISTINE D , COLLINS PETER L , MURPHY BRIAN R , BUCHHOLZ URSULA , WHITEHEAD STEPHEN S
发明人： KREMPL CHRISTINE D , COLLINS PETER L , MURPHY BRIAN R , BUCHHOLZ URSULA , WHITEHEAD STEPHEN S
IPC分类号： C12N15/09 , A61K39/12 , A61K39/155 , A61P31/14 , C12N7/00 , C12N7/02 , C12N7/04
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18562
摘要： Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, RSV glycoproteins are upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. A variety of additional mutations and nucleotide modifications are provided within the gene position-shifted RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：具有在重组病毒基因组或反基因组内转移的基因位点的重组呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性。基因移位的RSV通过在重组基因组或反基因组内插入，缺失或重排基因或基因组片段而构建，并可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和整合了重组RSV基因组或反基因组的载体，其中基因或基因片段在基因组或反基因组内与基因或野生型基因的野生型位置相比转移到更靠近启动子近端或启动子远端的位置 RSV基因图谱。根据位置转换的性质和程度，以这种方式移动基因的位置提供了所选基因表达的增加或减少。在一个实施方案中，通过将一种或多种糖蛋白编码基因转移到更靠近启动子的位置来上调RSV糖蛋白。用于操作以产生基因位置移位RSV的感兴趣基因包括NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因中的任一个或可能成为基因或外源基因的一部分。在本发明的位置移位RSV基因内提供多种额外的突变和核苷酸修饰以产生所需的表型和结构效应。

2. 发明申请

WO0104335A8 HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 审中-公开
标题翻译：人类猪流感呼吸道感染病毒疫苗
公开(公告)号：WO0104335A8
公开(公告)日：2003-02-06
申请号：PCT/US0017755
申请日：2000-06-23
申请人： US GOV HEALTH & HUMAN SERV , BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
发明人： BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。在本发明的优选方面，嵌合RSV包含与来自人RSV的一个或多个异源基因或基因组片段组合的部分或完整的牛RSV背景基因组或反向异构体。感兴趣的基因包括任何NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因或包含蛋白质或其部分的基因组片段。在本发明的人 - 牛嵌合RSV内提供了多种额外的突变和核苷酸修饰，以产生所需的表型和结构效果。

3. 发明申请

WO0104335A3 HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 审中-公开
标题翻译：人类猪流感呼吸道感染病毒疫苗
公开(公告)号：WO0104335A3
公开(公告)日：2002-12-19
申请号：PCT/US0017755
申请日：2000-06-23
申请人： US GOV HEALTH & HUMAN SERV , BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
发明人： BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。在本发明的优选方面，嵌合RSV包含与来自人RSV的一个或多个异源基因或基因组片段组合的部分或完整的牛RSV背景基因组或反向异构体。感兴趣的基因包括任何NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因或包含蛋白质或其部分的基因组片段。在本发明的人 - 牛嵌合RSV内提供了多种额外的突变和核苷酸修饰，以产生所需的表型和结构效果。

4. 发明申请

WO0061611A9 PRODUCTION OF ATTENUATED CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES 审中-公开
标题翻译：从克隆核苷酸序列中产生减毒的呼吸道同源病毒疫苗
公开(公告)号：WO0061611A9
公开(公告)日：2002-03-28
申请号：PCT/US0008802
申请日：2000-03-31
申请人： US HEALTH , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S
发明人： COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S
IPC分类号： C12N15/09 , A61K9/12 , A61K39/155 , A61P31/14 , C07K14/135 , C12N7/00 , C12N7/04 , C12N7/08 , C12R1/93 , C12N15/45
CPC分类号： C07K14/005 , A61K2039/5254 , C12N7/00 , C12N2760/18522 , C12N2760/18561
摘要： Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV background of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.
摘要翻译：嵌合呼吸道合胞病毒（RSV）及其疫苗组合物通过将一个或多个异源基因或基因区段从一个RSV亚组或菌株引入到不同亚组或菌株的受体RSV背景中来产生。所得到的嵌合RSV病毒或亚病毒颗粒是感染性和减毒性的，优选通过将指定减毒表型的选定突变引入到嵌合基因组或反基因组中以得到例如温度敏感（ts）和/或冷适应（ca）疫苗株。或者，嵌合RSV及其疫苗组合物掺入在感染性嵌合RSV中指定所需结构和/或表型特征的其它突变。这种嵌合RSV包含通过嵌合RSV克隆中的一个或多个选定的核苷酸序列，基因或基因片段的插入，缺失，取代或重排而指定的所需突变。这提供了通过使用共同的减毒骨架作为表达异源株的保护性抗原的载体来开发针对不同RSV菌株的新型疫苗的方法。刺激个体的免疫系统以诱导针对天然RSV感染的保护，优选以多价方式实现针对多个RSV菌株和/或亚组的保护。

5. 发明申请

WO0104271A3 RESPIRATORY SYNCYTIAL VIRUSES EXPRESSING IMMUNE MODULATORY MOLECULES 审中-公开
标题翻译：表达免疫调节分子的呼吸道同源病毒
公开(公告)号：WO0104271A3
公开(公告)日：2001-07-19
申请号：PCT/US0019042
申请日：2000-07-12
申请人： US HEALTH , COLLINS PETER L , BUKREYEV ALEXANDER , MURPHY BRIAN R , WHITEHEAD STEPHEN S
发明人： COLLINS PETER L , BUKREYEV ALEXANDER , MURPHY BRIAN R , WHITEHEAD STEPHEN S
IPC分类号： C12N15/09 , A61K9/12 , A61K35/76 , A61K39/00 , A61K39/155 , A61K48/00 , A61P11/00 , A61P11/06 , A61P31/14 , A61P37/04 , C07K14/54 , C12N7/00 , C12N7/04 , C12N15/86 , A61K38/17 , C07K14/14 , C12N15/62
CPC分类号： C07K14/54 , A61K39/00 , A61K48/00 , C07K2319/00 , C12N15/86 , C12N2760/18543 , C12N2840/20
摘要： Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.
摘要翻译：提供重组呼吸道合胞病毒（RSV），其表达一种或多种免疫调节分子。通过添加或取代编码免疫调节分子的多核苷酸序列来修饰重组病毒，所述多核苷酸序列优选是细胞因子。引入细胞因子增加，减少或以其他方式增强病毒生物学和/或宿主对RSV的免疫应答的方面以促进病毒的疫苗使用。用于本发明的细胞因子包括但不限于白介素2（IL-2），白细胞介素4（IL-4），白细胞介素5（IL-5），白介素6（IL-6）或白细胞介素18（IL- 18），肿瘤坏死因子（TNF）α，干扰素γ（IFN）和粒细胞巨噬细胞集落刺激因子（GM-CSF）。多核苷酸或免疫调节分子优选作为单独的基因添加或取代成重组病毒基因组或反向原子团，通常在基因间或其他非编码位点，但可另外表达为例如融合蛋白。

6. 发明申请

WO0061611A3 PRODUCTION OF ATTENUATED CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES 审中-公开
标题翻译：从克隆核苷酸序列中产生减毒的呼吸道同源病毒疫苗
公开(公告)号：WO0061611A3
公开(公告)日：2001-01-04
申请号：PCT/US0008802
申请日：2000-03-31
申请人： US HEALTH , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S
发明人： COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S
IPC分类号： C12N15/09 , A61K9/12 , A61K39/155 , A61P31/14 , C07K14/135 , C12N7/00 , C12N7/04 , C12N7/08 , C12R1/93 , C12N15/45
CPC分类号： C07K14/005 , A61K2039/5254 , C12N7/00 , C12N2760/18522 , C12N2760/18561
摘要： Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV background of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.
摘要翻译：嵌合呼吸道合胞病毒（RSV）及其疫苗组合物通过将一个或多个异源基因或基因区段从一个RSV亚组或菌株引入到不同亚组或菌株的受体RSV背景中来产生。所得到的嵌合RSV病毒或亚病毒颗粒是感染性和减毒性的，优选通过将指定减毒表型的选定突变引入到嵌合基因组或反基因组中以得到例如温度敏感（ts）和/或冷适应（ca）疫苗株。或者，嵌合RSV及其疫苗组合物掺入在感染性嵌合RSV中指定所需结构和/或表型特征的其它突变。这种嵌合RSV包含通过嵌合RSV克隆中的一个或多个选定的核苷酸序列，基因或基因片段的插入，缺失，取代或重排而指定的所需突变。这提供了通过使用共同的减毒骨架作为表达异源株的保护性抗原的载体来开发针对不同RSV菌株的新型疫苗的方法。刺激个体的免疫系统以诱导针对天然RSV感染的保护，优选以多价方式实现针对多个RSV菌株和/或亚组的保护。

7. 发明申请

WO2008022196A2 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS 审中-公开
标题翻译：登革热疫苗组分的研制
公开(公告)号：WO2008022196A2
公开(公告)日：2008-02-21
申请号：PCT/US2007076004
申请日：2007-08-15
申请人： US GOV HEALTH & HUMAN SERV , WHITEHEAD STEPHEN S , BLANEY JOSEPH E , MURPHY BRIAN R
发明人： WHITEHEAD STEPHEN S , BLANEY JOSEPH E , MURPHY BRIAN R
IPC分类号： C12N7/00
CPC分类号： C12N7/045 , A61K2039/5254 , C07K14/005 , C07K14/1825 , C12N7/00 , C12N2770/24122 , C12N2770/24162
摘要： The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3'-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3'-UTR that removes sequence in the 5' direction as far as the 5' boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3'-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
摘要翻译：本发明涉及在3'非翻译区（3'-UTR）中含有突变的登革热病毒或嵌合登革热病毒，其包含在每一登革病毒血清型1中除去TL-2同源结构的α30突变， 2,3和4以及从3'-UTR中删除的〜30个突变的核苷酸除去5'方向上的序列，直到每个登革热病毒中TL-3同源结构的5'边界血清型1,2,3和4，或用第二血清型登革病毒的3'-UTR替代第一血清型登革病毒的3'-UTR，任选含有Δ30突变和核苷酸从3'-UTR缺失的Δ30突变的附加物; 和免疫原性组合物，诱导免疫应答的方法，以及产生登革热病毒或嵌合登革病毒的方法。

8. 发明申请

WO2008121487A3 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE 审中-公开
标题翻译：洛杉矶蛇毒病毒和其他蝙蝠蛾的灭活病毒疫苗
公开(公告)号：WO2008121487A3
公开(公告)日：2009-03-19
申请号：PCT/US2008056099
申请日：2008-03-06
申请人： US GOV HEALTH & HUMAN SERV , WHITEHEAD STEPHEN S , BENNETT RICHARD S , MURPHY BRIAN R
发明人： WHITEHEAD STEPHEN S , BENNETT RICHARD S , MURPHY BRIAN R
IPC分类号： C07K14/175 , A61K39/12
CPC分类号： A61K39/12 , A61K39/00 , A61K2039/5252 , A61K2039/5254 , C07K14/005 , C12N7/00 , C12N2760/12022 , C12N2760/12034 , C12Q1/701
摘要： The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
摘要翻译：本发明涉及包含CEV血清群免疫原，CEV血清群和嵌合布尼亚病毒科的减毒和灭活病毒的疫苗组合物。还公开了在哺乳动物宿主中治疗或预防CEV血清群感染的方法，产生亚单位疫苗组合物或免疫原性组合物的方法，包含编码CEV血清组免疫原的核苷酸序列的分离的多核苷酸，用于检测拉克罗斯病毒（LACV）感染的方法在生物样品和感染性嵌合布尼病病毒科。

9. 发明专利

DK1402075T3 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira 未知
公开(公告)号：DK1402075T3
公开(公告)日：2013-02-11
申请号：DK02739358
申请日：2002-05-22
申请人： US GOV NAT INST HEALTH
发明人： HANLEY KATHRYN A , WHITEHEAD STEPHEN S , MURPHY BRIAN R , BLANEY JOSEPH E JR
IPC分类号： C12Q1/70 , A61K39/12 , A61K39/193 , A61K39/295 , A61K39/42 , C07H21/02 , C07H21/04 , C07K1/00 , C07K14/00 , C07K17/00 , C12N7/00 , C12N7/01 , C12N7/04 , C12P19/34 , C12Q1/68 , G01N33/48 , G01N33/53

10. 发明专利

CA2378552A1 PRODUCTION OF ATTENUATED, HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 未知
公开(公告)号：CA2378552A1
公开(公告)日：2001-01-18
申请号：CA2378552
申请日：2000-06-23
申请人： GOVERNMENT OF THE US DEP ART , BUCHHOLZ URSULA
发明人： COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D , BUCHHOLZ URSULA
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations fo r eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeri c human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine R SV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene( s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segme nt including a protein or portion thereof. A variety of additional mutations an d nucleotide modifications are provided within the human-bovine chimeric RSV o f the invention to yield desired phenotypic and structural effects.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式